Gynecological Cancer Clinical Trials
To Participate in any of these clinical trials or for more information:
Call us at (808) 586-2979
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Study Number | Study Details |
|---|---|
NRG-GY019 Local Principal Investigator: | Official Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Enrollment Status: Open: KMCWC, Pali Momi, QMC Cancer Type: Gynecological Keywords: Adjuvant Subtype: Ovarian/Fallopian/Primary Peritoneal ClinicalTrials.gov ID: NCT04095364 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-GY026 Local Principal Investigator: | Official Title: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Enrollment Status: Open: KMCWC, QMC Cancer Type: Gynecological Keywords: Chemo-naive / Non-recurrent Subtype: Ovarian/Fallopian/Primary Peritoneal ClinicalTrials.gov ID: NCT05256225 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
DB-1303-O-1001 Local Principal Investigator: | Official Title: A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors Enrollment Status: Open: KMCWC only Cancer Type: Gynecological Keywords: Advanced / Recurrent Subtype: Ovarian/Fallopian/Primary Peritoneal ClinicalTrials.gov ID: NCT05150691 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EAY191-N4 Local Principal Investigator: | Official Title: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial Enrollment Status: Open: KMCWC, QMC Cancer Type: Gynecological Keywords: ComboMATCH Subtype: Corpus Uteri/Ovary ClinicalTrials.gov ID: NCT05554328 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
